Press releases
GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the European Union for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline and Amicus Therapeutics announce top-line six-month primary treatment period results from first Phase III Fabry monotherapy study
GlaxoSmithKline plc (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced the six-month primary treatment period results from the first Phase III global registration study (Study 011) of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay.
GSK and Theravance announce regulatory submission for UMEC/VI (LAMA/LABA) in the US
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).
ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada
London, UK - 17 December, 2012 – ViiV Healthcare today announced the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S/GSK1349572) for the treatment of HIV infection in adults and adolescents
FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX® QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
GSK receives FDA approval for raxibacumab anti-toxin for the treatment of inhalational anthrax
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique
GSK today announced it has formed a partnership with Vodafone to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa.
GSK welcomes the publication of the 2012 Access to Medicines Index
GSK welcomes the publication of the third Access to Medicines (ATM) Index, which measures the performance of the top 20 pharmaceutical companies on their efforts to improve access to medicines and healthcare in developing countries.
GSK announces agreement in principle to increase its stake in GlaxoSmithKline Consumer Nigeria PLC
GlaxoSmithKline plc (“GSK”) (LSE: GSK) and GlaxoSmithKline Consumer Nigeria PLC (“GSK Nigeria” or the “Company”) today announced that they have reached agreement in principle on the terms of a proposal whereby GSK would increase its ownership in the Company from 46.4% to 80% (the “Proposal”).
